AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) ($M)
Form 6-K Quarterly & Form 20-F Product Sales by Therapy Area & Region Tables
Latest, FY2025
12,764
Period ended Dec 31, 2025
Change on a year earlier
+2.5%
12,448 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12,764 | +2.5% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 12,448 | +17.6% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 10,585 | +15.2% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 9,188 | +14.6% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 8,020 | +13.0% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 7,096 | +2.8% | Form 6-K FY2020Q4 Earnings Release ↗ |
| FY2019 | Dec 31, 2019 | 6,906 | +2.9% | Form 20-F (filed 2020-03-03) ↗ |
| FY2018 | Dec 31, 2018 | 6,710 | -7.7% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 7,266 | -10.5% | Form 20-F (filed 2019-03-05) ↗ |
| FY2016 | Dec 31, 2016 | 8,116 | – | Form 20-F (filed 2019-03-05) ↗ |
Breakdown
What makes up cardiovascular, renal & metabolism (cvrm) — worldwide product sales ($m)
- Cardiovascular, Renal & Metabolism (CVRM) — Worldwide YoY actual (%)3.0% · FY2025
- Cardiovascular, Renal & Metabolism (CVRM) — Worldwide YoY CER (%)2.0% · FY2025
- Cardiovascular, Renal & Metabolism (CVRM) — US product sales ($M)2,722 · FY2025
- Cardiovascular, Renal & Metabolism (CVRM) — Emerging Markets product sales ($M)5,893 · FY2025
- Cardiovascular, Renal & Metabolism (CVRM) — Europe product sales ($M)3,398 · FY2025
- Cardiovascular, Renal & Metabolism (CVRM) — Established RoW product sales ($M)751 · FY2025
- Farxiga / Forxiga (dapagliflozin) — Worldwide product sales ($M)8,400 · FY2025
- Lokelma (sodium zirconium cyclosilicate) — Worldwide product sales ($M)698 · FY2025
- Brilinta / Brilique (ticagrelor) — Worldwide product sales ($M)823 · FY2025
- Crestor (rosuvastatin) — Worldwide product sales ($M)1,216 · FY2025
- Seloken / Toprol-XL (metoprolol) — Worldwide product sales ($M)607 · FY2025
- Roxadustat (evrenzo) — Worldwide product sales ($M)274 · FY2025
- Wainua (eplontersen) — Worldwide product sales ($M)212 · FY2025
- Other CVRM medicines — Worldwide product sales ($M)534 · FY2025
Cite this data
StockData. (2026). AstraZeneca Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta_cvrm_world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.